These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22594682)

  • 21. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
    Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
    Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Tyrosine Kinase Inhibitor-masitinib Mesylate on Canine Mammary Tumour Cell Lines.
    Ustun-Alkan F; Bakırel T; Üstüner O; Anlas C; Cinar S; Yıldırım F; Gürel A
    J Vet Res; 2021 Sep; 65(3):351-359. PubMed ID: 34917849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
    Lee-Fowler TM; Guntur V; Dodam J; Cohn LA; DeClue AE; Reinero CR
    Int Arch Allergy Immunol; 2012; 158(4):369-74. PubMed ID: 22487554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma.
    Fukumoto S; Saida K; Sakai H; Ueno H; Iwano H; Uchide T
    Life Sci; 2016 Aug; 159():55-60. PubMed ID: 26835989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
    Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
    Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Elders RC; Baines SJ; Catchpole B
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
    Devine L; Polzin DJ
    Can Vet J; 2016 Jul; 57(7):752-6. PubMed ID: 27429464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.
    Takeuchi Y; Fujino Y; Fukushima K; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
    J Vet Pharmacol Ther; 2012 Feb; 35(1):97-104. PubMed ID: 21480930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-proliferative and apoptotic effects of the novel taspine derivative tas41 in the Caco-2 cell line.
    Zhang Y; Zhang J; Dai B; Wang N; He L
    Environ Toxicol Pharmacol; 2011 May; 31(3):406-15. PubMed ID: 21787711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro cytotoxicity of cyclodextrin-bonded birch bark extract.
    Hertrampf A; Gründemann C; Jäger S; Laszczyk M; Giesemann T; Huber R
    Planta Med; 2012 Jun; 78(9):881-9. PubMed ID: 22573365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
    Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G; Timeus F; Rinaldi A; Crescenzio N; Spinelli M; Rosolen A; Ricotti E; Basso G
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
    Gulay KCM; Aoshima K; Shibata Y; Yasui H; Yan Q; Kobayashi A; Kimura T
    J Genet Genomics; 2021 Jul; 48(7):618-630. PubMed ID: 34023294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of masitinib mesylate in healthy cats.
    Daly M; Sheppard S; Cohen N; Nabity M; Moussy A; Hermine O; Wilson H
    J Vet Intern Med; 2011; 25(2):297-302. PubMed ID: 21314730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
    Cadot P; Hensel P; Bensignor E; Hadjaje C; Marignac G; Beco L; Fontaine J; Jamet JF; Georgescu G; Campbell K; Cannon A; Osborn SC; Messinger L; Gogny-Goubert M; Dubreuil P; Moussy A; Hermine O
    Vet Dermatol; 2011 Dec; 22(6):554-64. PubMed ID: 21668810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006).
    Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL
    J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.